Bleeding and Clotting Disorders
Protocol:ALN-AT3SC-004
Condition or Disease: Hemophilia A or B
Study Type: Interventional (Clinical Trial)
Status: Open for enrollment
Study Title: ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX
Principal I investigator: Joseph Lasky III, MD
More Info: //clinicaltrials.gov/ct2/show/NCT03417245
The Rare Disease Advisory Council is seeking input from the public to help improve the health of Nevada residents. The council is focused on addressing the needs of those with rare diseases and is looking for feedback from patients, caregivers, and healthcare providers. The goal is to gather information that can be used to develop strategies and policies to improve the lives of those affected by rare diseases in Nevada.
Cure 4 The Kids Foundation is pleased to announce the appointment of Christine Tonn as its new chief executive officer (CEO), effective January 1, 2024. This promotion is part of a board of directors-supported management succession plan.
